跳至主要内容
临床试验/NCT01670786
NCT01670786已完成4 期

Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion

Grupo de Pesquisa em Pleura e Oncologia Toracica1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2010年1月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
Safety of iodopovidone as an agent for pleurodesis

研究概览

简要总结

Iodopovidone is safe when using as a pleurodesis sclerosing agent for malignant pleural effusion, with minimal adverse events, especially reducing dose.

详细描述

Background: Chemical pleurodesis is the treatment of choice in most cases of malignant pleural effusion. The literature mentions a variety of chemicals which may be used for this purpose, each with its own advantages and disadvantages. The iodopovidone has been recently studied due to the existence of some side effects of other agents. Nevertheless, there are still some questions in the literature regarding its safety and possible adverse effects. Because of these questions, we propose the development of a study to ensure the safety and efficacy of iodopovidone as a pleurodesis sclerosing agent.

Objective

The main purpose of this study is to evaluate the safety of pleurodesis for malignant pleural effusion using iodopovidone as a sclerosing agent in different doses. The secondary objectives are to determine clinical efficacy and quality of life of the patients after realization of the proposed procedure.

Methods: There will be a randomized clinical trial, covering patients diagnosed with malignant pleural effusion at Hospital Aristides Maltez - Bahia League Against Cancer. The research was revised and approved by the Ethics in Research of the Heart Institute, Hospital das Clínicas - FMUSP and of the Hospital Aristides Maltez - Bahia League Against Cancer. The free and informed consent was evaluated by the same authority pursuant and the study group included only those who agree to participate and signed an approved. There included patients with malignant pleural effusion diagnosis. Main exclusion criteria were iodine allergia, renal failure, thyroid disease, refusal to sign the informed consent and patients unable to respond the quality of life questionnaire. After inclusion, patients were randomized and assigned to two groups according to the iodopovidone concentration solution: 1% or 2%. All procedures were performed by infusion of the solution through a chest tube previously placed.The data analysis involved clinical measures and complementary exams trying to evaluate all organ systems and sorting through possible adverse effects, classifying those as CTCAEV. Clinical measures involved MRC dyspnea schedule, analogic visual pain schedule, visual acuity test, measurement of pulse oximetry, heart rate, blood pressure and temperature. Complementary exams were chest x-ray, electrocardiogram and laboratory tests. Such measures were performed in the preoperative, immediate postoperative, second, fourth, eleventh and thirty days postoperative. Quality of life questionnaires was applied before and on thirty days postoperative as well. After that, randomized groups were compared.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • malignant pleural effusion
  • Recurrent pleural effusion
  • Complete lung expansion (> 80%) after puncture emptying confirmed by chest radiography.
  • Karnofsky index >
  • Agreed to participate in the study and sign an Informed Consent

排除标准

  • Thrombocytopenia or coagulation disorders
  • Patients with impaired renal function
  • Pleural or active systemic infection
  • Massive neoplastic infiltration of the skin
  • Inability to understand the quality of life questionnaire
  • Previous pleural procedures
  • Allergy to iodine
  • Thyroid disorders

结局指标

主要结局

Safety of iodopovidone as an agent for pleurodesis

时间窗: Until 30th day after surgical procedure

The safety was assessed by mean clinical measures as MRC dyspnea schedule, analogic visual pain schedule, visual acuity test, measurement of pulse oximetry, heart rate, blood pressure and temperature. Complementary exams were chest x-ray, electrocardiogram and laboratory tests.

次要结局

  • Quality of life(Until 1 week before the procedure date and 1 month after it)

研究者

发起方
Grupo de Pesquisa em Pleura e Oncologia Toracica
申办方类型
Network
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验